CLINICAL TRIAL
JOURNAL ARTICLE
RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
Add like
Add dislike
Add to saved papers

Effect of intravenous immunoglobulin therapy on serum levels of IgG1 and IgG4 antidesmoglein 1 and antidesmoglein 3 antibodies in pemphigus vulgaris.

BACKGROUND: Intravenous immunoglobulin rapidly decreases serum levels of intercellular antibodies in patients with pemphigus vulgaris. However, little is known about the effects of this therapy on antibodies directed specifically against desmoglein 1 and desmoglein 3 and on the IgG subclasses of these antibodies. This study was conducted to study the effect of intravenous immunoglobulin therapy on serum levels of IgG1 and IgG4 antibodies against desmoglein 1 and desmoglein 3 in patients with pemphigus vulgaris.

OBSERVATIONS: Within 6 to 16 days after initiating a single cycle of intravenous immunoglobulin therapy in 9 patients, a significant decrease in serum levels of IgG4 and IgG1 antibodies against desmoglein 1 and desmoglein 3 occurred in 60% to 100% of the patients, depending on the antibody subclass and specificity. The median decrease in the antibody levels ranged from 34% to 80%. In addition, most patients (n = 6) showed clinical improvement. The decrease in IgG4 antidesmoglein 3 levels seemed to correlate with improvement in disease activity.

CONCLUSIONS: Intravenous immunoglobulin therapy rapidly lowers serum levels of IgG1 and IgG4 antidesmoglein 1 and desmoglein 3 antibodies. There seems to be a stronger association between the decrease in IgG4 antidesmoglein 3 levels and improvement in clinical activity than with changes in the other antibody levels, which suggests that IgG4 antibodies have a more important role in mediating pemphigus vulgaris.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app